- Home
- KTF vs MREO Comparison
KTF vs MREO Comparison
Compare KTF & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KTF | MREO |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.0M | 67.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | KTF | MREO |
|---|---|---|
| Price | $9.14 | $0.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 90.6K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | $23.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.48 | $0.20 |
| 52 Week High | $9.50 | $2.94 |
Technical Indicators
Market Signals| Indicator | KTF | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 39.30 |
| Support Level | $9.13 | $0.35 |
| Resistance Level | $9.29 | $0.45 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 17.50 | 53.37 |
Price Performance
Historical ComparisonAbout KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).